[Pituitary tumors: 10 years of experience].
BACKGROUND
Pituitary tumors comprise a quarter of the intracranial neoplasms and the adenomas represent the highest percentage of them. They are benign, but they can be invasive and they have an impact in morbidity and mortality.


OBJECTIVE
To analyze the clinical features of pituitary adenomas tumors, and create a computerized registry to improve strategies for diagnosis and monitoring of these patients.


METHODS
A retrospective, descriptive analysis of 102 medical records of a total of 191 patients who attended the endocrinology service from 2003 to 2014 .The variables were analyzed by the corresponding descriptive statistics. The SPSS 11.5 was used.


RESULTS
63% were women, and (74.4%) had age from 25-60 years. 54% were nonfunctioning adenomas, 28% to prolactinomas, 11.8% and 6.2% somatotropinomas corticotropinomas. In all types the female group was predominant, except nonfunctioning. Of the nonfunctioning adenomas 79% were macroadenomas, prolactinomas 52% were microadenomas and surgery was performed in 37% of them. The somatotropinomas, 80% were macroadenomas, 80% of patients and 40% radiotherapy was operated. In corticotropinomas, both micro and macroadenomas were submitted by the same percentage (50%) and all of them underwent surgery.


CONCLUSIONS
The findings are consistent with the literature in terms of frequency and age of onset of adenomas. We suggest the development of a registry to optimize the monitoring and treatment of patients, research and scientific publication.
Laura Anahi
LA
Cecenarro
Elica Tatiana
ET
Rodrigo Fanton
Paula
P
Estario
Roque Francisco
RF
Papalini
María Éugenia
MÉ
Estario
D000236:Adenoma / Q000145:classification* / Q000473:pathology / Q000628:therapy; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D010911:Pituitary Neoplasms / Q000145:classification* / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies; D012959:Socioeconomic Factors; D016896:Treatment Outcome